Nuvectis Pharma 10% holder boosts position with $270k open-market buy

Rhea-AI Filing Summary

Key take-away: Nuvectis Pharma, Inc. (NVCT) filed a Form 4 showing that 10% owner Charles Mosseri-Marlio, via Emerald Hill Ventures SARL SPF, bought 33,442 common shares in two open-market transactions on 17-18 Jun 2025.

• Prices: weighted-average $8.11 on 17 Jun for 5,399 shares and $8.05 (range $7.91-$8.11) on 18 Jun for 28,043 shares.
• Post-purchase holdings: 2,976,203 shares held indirectly, up from 2,942,761.
• Transaction code “P” confirms open-market purchases; no 10b5-1 plan indicated.
• No derivative securities or sales reported; filing does not include earnings or operational metrics.

The estimated cash outlay is roughly $270k; insider accumulation at market prices often signals management’s confidence and can be viewed as a bullish indicator by investors. Because the investor already owns more than 10% of NVCT, the additional purchase marginally increases an already significant stake and reinforces alignment with minority shareholders.

Positive

• 10% owner purchased 33,442 shares in open-market transactions, signaling insider confidence.
• Total indirect holdings increased to 2,976,203 shares, reinforcing alignment with minority investors.

Negative

• None.

Insights

Securities Analyst

TL;DR: Large insider increases stake by 33k shares at ~$8; signals confidence, no negative flags.

The filing shows pure open-market buying by a 10% holder, with no offsetting sales or derivatives. The dollar value is modest versus a 2.98 m share position, yet insider purchases—especially during non-blackout periods—often precede positive news or reflect undervaluation perceptions. NVCT trades near $8; using the last reported basic share count (not provided here), the insider’s stake likely remains >10%, maintaining strong voting influence. No 10b5-1 box checked means discretional buying, heightening the signal. Because no operational data accompany the filing, the impact is sentiment-driven rather than fundamental, but in micro-cap biotech names such moves can support share price momentum.

Corporate Governance Expert

TL;DR: Transaction is governance-neutral; beneficial owner deepens alignment without triggering control thresholds.

From a governance angle, the purchase marginally increases an existing controlling-class holding yet does not surpass any new reporting thresholds or require a Schedule 13D amendment. The lack of a 10b5-1 plan suggests opportunistic timing, allowable under SEC rules absent MNPI. No red flags on reporting timeliness (filed within two business days). The continued accumulation supports shareholder alignment but does not materially shift board dynamics because Mosseri-Marlio was already a major holder. Impact therefore skews positive but limited in magnitude.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mosseri Marlio Charles

(Last) (First) (Middle)

27 RIPPLEVALE GROVE

(Street)

LONDON N1 1HS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		P		5,399	A	$8.11	2,948,160(1)	I	By Emerald Hill Ventures SARL SPF.
Common Stock	06/18/2025		P		28,043	A	$8.05(2)	2,976,203(1)	I	By Emerald Hill Ventures SARL SPF.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL.

2. Reflects the weighted average purchase price. The range of prices for the shares purchased was $7.91 to $8.11. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Charles Mosseri-Marlio	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NVCT shares did the insider buy?

The insider purchased 33,442 common shares on 17-18 Jun 2025.

At what price were the NVCT shares acquired?

Shares were bought at a weighted-average $8.11 on 17 Jun and $8.05 (range $7.91-$8.11) on 18 Jun.

What is the insider's total NVCT ownership after these transactions?

After the purchases, the insider indirectly owns 2,976,203 shares of NVCT.

Was a 10b5-1 trading plan used for these NVCT transactions?

No. The Form 4 did not indicate that the trades were executed under a 10b5-1 plan.

Did the filing include any derivative securities or sales?

No. The Form 4 reported only open-market purchases of common stock; no derivatives or sales were disclosed.